Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2005 2
2006 1
2007 5
2008 3
2009 11
2010 8
2011 16
2012 13
2013 16
2014 16
2015 15
2016 17
2017 15
2018 18
2019 18
2020 23
2021 34
2022 22
2023 31
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Results by year

Filters applied: . Clear all
Page 1
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Müller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, Klein SA, Schubert J, Niederland J, Kaufmann M, Schäfer-Eckart K, Schaich M, Baldauf H, Stölzel F, Petzold C, Röllig C, Alakel N, Steffen B, Hauptrock B, Schliemann C, Sockel K, Lang F, Kriege O, Schaffrath J, Reicherts C, Berdel WE, Serve H, Ehninger G, Schmidt AH, Bornhäuser M, Mikesch JH, Schetelig J; Study Alliance Leukemia and the German Cooperative Transplant Study Group. Stelljes M, et al. Among authors: klein sa. Lancet Haematol. 2024 May;11(5):e324-e335. doi: 10.1016/S2352-3026(24)00065-6. Epub 2024 Apr 4. Lancet Haematol. 2024. PMID: 38583455 Free article. Clinical Trial.
The oral IRAK4 inhibitors zabedosertib and BAY1830839 suppress local and systemic immune responses in a randomized trial in healthy male volunteers.
Jodl SJ, Ten Voorde W, Klein S, Wagenfeld A, Zollmann FS, Feldmüller M, Klarenbeek NB, de Bruin DT, Jansen MAA, Rissmann R, Rohde B, Moerland M. Jodl SJ, et al. Among authors: klein s. Clin Transl Sci. 2024 Mar;17(3):e13771. doi: 10.1111/cts.13771. Clin Transl Sci. 2024. PMID: 38511583 Free PMC article. Clinical Trial.
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.
Lübke J, Christen D, Schwaab J, Kaiser A, Naumann N, Shoumariyeh K, Jentzsch M, Sockel K, Schaffrath J, Ayuk FA, Stelljes M, Hilgendorf I, Sala E, Kaivers J, Schönland S, Wittke C, Hertenstein B, Radsak M, Kaiser U, Brückl V, Kröger N, Brümmendorf TH, Hofmann WK, Klein S, Jost E, Reiter A, Panse J. Lübke J, et al. Among authors: klein s. Leukemia. 2024 Apr;38(4):810-821. doi: 10.1038/s41375-024-02186-x. Epub 2024 Mar 6. Leukemia. 2024. PMID: 38448757 Free PMC article.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Mai EK, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, Fenk R, Schlenzka J, Munder M, Dürig J, Blau IW, Huhn S, Hose D, Jauch A, Kunz C, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A, Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens UM, Kunz C, Hensel M, Benner A, Seidel-Glätzer A, Weisel KC, Raab MS, Salwender HJ; German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators. Mai EK, et al. Lancet Haematol. 2024 Feb;11(2):e101-e113. doi: 10.1016/S2352-3026(23)00366-6. Lancet Haematol. 2024. PMID: 38302221 Free article. Clinical Trial.
New retinoblastoma (RB) drug delivery approaches: anti-tumor effect of atrial natriuretic peptide (ANP)-conjugated hyaluronic-acid-coated gold nanoparticles for intraocular treatment of chemoresistant RB.
Haase A, Miroschnikov N, Klein S, Doege A, Dünker N, Van Meenen D, Junker A, Göpferich A, Apaolaza PS, Busch MA. Haase A, et al. Among authors: klein s. Mol Oncol. 2024 Apr;18(4):832-849. doi: 10.1002/1878-0261.13587. Epub 2024 Jan 12. Mol Oncol. 2024. PMID: 38217258 Free PMC article.
ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party.
Penack O, Peczynski C, Boreland W, Lemaitre J, Afanasyeva K, Kornblit B, Jurado M, Martinez C, Natale A, Pérez-Simón JA, Brunello L, Avenoso D, Klein S, Ozkurt ZN, Herrera C, Wichert S, Chiusolo P, Gavriilaki E, Basak GW, Schoemans H, Koenecke C, Moiseev I, Peric Z. Penack O, et al. Among authors: klein s. Front Immunol. 2023 Dec 11;14:1283034. doi: 10.3389/fimmu.2023.1283034. eCollection 2023. Front Immunol. 2023. PMID: 38149251 Free PMC article.
Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort.
van Garderen KA, Vallentgoed WR, Lavrova A, Niers JM, de Leng WWJ, Hoogstrate Y, de Heer I, Ylstra B, van Dijk E, Klein S, Draaisma K, Robe PAJT, Verhaak RGW, Westerman BA, French PJ, van den Bent MJ, Kouwenhoven MCM, Kros JM, Wesseling P, Smits M. van Garderen KA, et al. Among authors: klein s. Neurooncol Adv. 2023 Nov 9;5(1):vdad149. doi: 10.1093/noajnl/vdad149. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 38024241 Free PMC article.
246 results